Bragar Eagel & Squire, P.C. announced that a class action lawsuit has been filed against ADMA Biologics, Inc. in the United States District Court for the District of New Jersey. The lawsuit represents purchasers of ADMA securities between August 9, 2024 and March 25, 2026, and alleges that the company made false statements and failed to disclose material facts, including an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. On March 24, 2026, Culper Research published a short report claiming ADMA's reported growth was driven by a channel stuffing scheme and an undisclosed related party distributor, estimating that without channel stuffing, revenues declined 3% in 2025 versus a reported 20% increase. Following the report, ADMA's stock fell $2.26 per share, or 16.63%, to close at $11.33. Investors have until August 10, 2026 to seek lead plaintiff appointment.
ADMA Biologics IncClass action lawsuit alleging channel stuffing and undisclosed related party transaction, causing stock drop.